Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $87.9 million.

  • Pharming Group N.V's Total Current Liabilities rose 10.11% to $87.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.9 million, marking a year-over-year increase of 10.11%. This contributed to the annual value of $73.8 million for FY2024, which is 5.34% down from last year.
  • Latest data reveals that Pharming Group N.V reported Total Current Liabilities of $87.9 million as of Q3 2025, which was down 0.03% from $87.9 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Total Current Liabilities registered a high of $207.3 million during Q1 2024, and its lowest value of $46,694 during Q3 2022.
  • For the 3-year period, Pharming Group N.V's Total Current Liabilities averaged around $87.7 million, with its median value being $78.0 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 99.90% in 2022, then spiked by 145,653.20% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Total Current Liabilities stood at $46.8 million in 2021, then grew by 27.64% to $59.7 million in 2022, then skyrocketed by 30.60% to $78.0 million in 2023, then declined by 5.34% to $73.8 million in 2024, then increased by 10.11% to $87.9 million in 2025.
  • Its Total Current Liabilities stands at $87.9 million for Q3 2025, versus $87.9 million for Q2 2025 and $77.5 million for Q1 2025.